Follow
Stefan Steidl
Title
Cited by
Year
Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
S Steidl, S Härtle, R Boxhammer
US Patent App. 18/548,477, 2024
2024
Anti-cd38 antibodies and their uses
S Steidl, S Härtle, R Boxhammer
US Patent App. 18/261,376, 2024
2024
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
RL Sakemura, C Manriquez Roman, P Horvei, EL Siegler, JH Girsch, ...
Blood 143 (3), 258-271, 2024
62024
Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models
RL Sakemura, CM Roman, LK Mai, BL Kimball, T Huynh, JM Feigin, ...
Blood 142, 6796, 2023
12023
TRANSIENT CD19 MASKING WITH TAFASITAMAB DIMINISHES CART19 APOPTOSIS AND TUMOR PYROPTOSIS, RESULTING IN INCREASED THERAPEUTIC INDEX OF CART19 THERAPY IN PRECLINICAL MODELS
R Sakemura, CM Roman, K Ilieva, C Augsberger, M Patra-Kneuer, ...
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 98-99, 2023
2023
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
M Patra-Kneuer, G Chang, W Xu, C Augsberger, M Grau, M Zapukhlyak, ...
Frontiers in immunology 14, 1220558, 2023
12023
Transient CD19 Occupancy with Tafasitamab at the Time of Anti-CD19 Chimeric Antigen Receptor T (CART19) Cell Infusion Diminishes Severity and Incidence of CRS and Improves the …
RL Sakemura, CM Roman, P Horvei, TN Huynh, JH Girsch, O Sirpilla, ...
2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023
2023
Uso de um anticorpo específico para cd19
J Amersdorffer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
2022
Blocking the cd47-sirpa axis enhances tafasitamab-mediated phagocytosis
A Biedermann, D Mangelberger-Eberl, D Mougiakakos, M Büttner-Herold, ...
Blood 140 (Supplement 1), 9292-9293, 2022
12022
CD19 antigen occupancy on cancer cells with the CD19 monoclonal antibody tafasitamab improves the activation, antitumor efficacy, and safety profile of CART19 cell therapy
RL Sakemura, C Manriquez-Roman, P Horvei, MJ Cox, T Huynh, ...
Blood 140 (Supplement 1), 2362-2364, 2022
32022
Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
JH Her, D Pretscher, M Patra-Kneuer, J Schanzer, SY Cho, YK Hwang, ...
Cancer Immunology, Immunotherapy 71 (11), 2829-2836, 2022
72022
Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom
J Amersdorfer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
2022
Kombinovana terapija sa anti-cd19 antitelom i analogom purina
J Amersdorffer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
2022
Anti-CD19 vasta-aineesta ja typpisinapista koostuva yhdistelmähoito
J Amersdorfer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
2022
Anti-CD19 vasta-aineesta ja puriinianalogista koostuva yhdistelmähoito
J Amersdorffer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
2022
Uso de um anticorpo anti-gm-csf
S Härtle, S Leclair, A Shebl, S Steidl
2022
Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep
M Winderlich, S Krohn, L Rojkjaer, J Amersdorfer, S Steidl
2022
Kombinationsterapi med et anti-cd19-antistof og en purin-analog
S Steidl, M Winderlich, S Krohn, L Rojkjaer, J Amersdorffer
2022
Combination therapy with an anti-cd19 antibody and a nitrogen mustard
J AMERSDORFER, S Steidl, M Winderlich, S Krohn, L Rojkjaer
12022
Combination therapy with an anti-CD19 antibody and a purine analog
J Amersdorffer, S Steidl, M Winderlich, S Krohn, L Rojkjaer
62022
The system can't perform the operation now. Try again later.
Articles 1–20